Controlling the Covalent Reactivity of a Kinase Inhibitor with Light

Covalent kinase inhibitors account for some of the most successful drugs that have recently entered the clinic and many others are in preclinical development. A common strategy is to target cysteines in the vicinity of the ATP binding site using an acrylamide electrophile. To increase the tissue selectivity of kinase inhibitors, it could be advantageous to control the reactivity of these electrophiles with light. Here, we introduce covalent inhibitors of the kinase JNK3 that function as photoswitchable affinity labels (PALs). Our lead compounds contain a diazocine photoswitch, are poor non-covalent inhibitors in the dark, and become effective covalent inhibitors after irradiation with visible light. Our proposed mode of action is supported by X-ray structures that explain why these compounds are unreactive in the dark and undergo proximity-based covalent attachment following exposure to light.

Automated summary

Covalent kinase inhibitors have shown success in recent clinical trials, with a strategy to control the reactivity of electrophiles using light to increase tissue selectivity. Researchers have developed covalent inhibitors for the kinase JNK3, which become effective inhibitors after exposure to light, supported by X-ray structures.